{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:51:04Z","timestamp":1792813864942,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T00:00:00Z","timestamp":1605312000000},"content-version":"am","delay-in-days":318,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Fondazione AIRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Italian Ministry of Health"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.cpet.2019.08.011","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T17:11:06Z","timestamp":1573751466000},"page":"23-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Current Evidence on PET Response Assessment to Immunotherapy in Lymphomas"],"prefix":"10.1016","volume":"15","author":[{"given":"Egesta","family":"Lopci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Meignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpet.2019.08.011_bib2","first-page":"1","volume":"276","author":"Nauts","year":"1953","journal-title":"Acta Med Scand Suppl"},{"key":"10.1016\/j.cpet.2019.08.011_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cpet.2019.08.011_bib4","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1007\/s00259-017-3802-5","article-title":"Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors","volume":"44","author":"Rossi","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2019.08.011_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"31","key":"10.1016\/j.cpet.2019.08.011_bib6","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2019.08.011_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/MOH.0000000000000158","article-title":"Targeting immune checkpoints in lymphoma","volume":"22","author":"Ansell","year":"2015","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"10.1016\/j.cpet.2019.08.011_bib8","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/CCO.0000000000000212","article-title":"Targeting the programmed death-1\/programmed death-ligand 1 axis in lymphoma","volume":"27","author":"Cheah","year":"2015","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.cpet.2019.08.011_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.humpath.2016.03.005","article-title":"Evaluation of the diagnostic and prognostic value of PD-L1 expression in Hodgkin and B-cell lymphomas","volume":"54","author":"Menter","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.cpet.2019.08.011_bib10","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1\u2013PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma","volume":"111","author":"Yamamoto","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cpet.2019.08.011_bib11","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2019.08.011_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-019-0185-9","article-title":"Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma","volume":"19","author":"Jalali","year":"2019","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.cpet.2019.08.011_bib13","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/2326-6066.CIR-18-0890","article-title":"The highs and lows of immune-checkpoint blockade in lymphoma","volume":"7","author":"Ansell","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"19","key":"10.1016\/j.cpet.2019.08.011_bib14","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2019.08.011_bib15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3389\/fonc.2018.00351","article-title":"Cancer immunotherapy in diffuse large B-cell lymphoma","volume":"8","author":"Zhang","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.cpet.2019.08.011_bib16","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2019.08.011_bib17","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001622-199811000-00012","article-title":"Use of rituximab, the new FDA-approved antibody","volume":"10","author":"Leget","year":"1998","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.cpet.2019.08.011_bib18","doi-asserted-by":"crossref","first-page":"8516","DOI":"10.1200\/jco.2015.33.15_suppl.8516","article-title":"Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas","volume":"33","author":"Schuster","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.cpet.2019.08.011_bib19","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cpet.2019.08.011_bib24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0167-5699(94)90274-7","article-title":"The CD19\/CD21 signal transduction complex of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol Today"},{"issue":"7","key":"10.1016\/j.cpet.2019.08.011_bib25","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","article-title":"Total costs of chimeric antigen receptor T-cell immunotherapy","volume":"4","author":"Hernandez","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2019.08.011_bib26","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/cancers10060204","article-title":"The role of immune checkpoint inhibitors in classical Hodgkin lymphoma","volume":"10","author":"Neti","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cpet.2019.08.011_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1200\/EDBK_200643","article-title":"Patterns of response and progression to immunotherapy","volume":"38","author":"Borcoman","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"14","key":"10.1016\/j.cpet.2019.08.011_bib28","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2019.08.011_bib29","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors","volume":"33","author":"Chiou","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.cpet.2019.08.011_bib30","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2019.08.011_bib31","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification response criteria for lymphoma in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cpet.2019.08.011_bib32","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.cpet.2019.08.011_bib33","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","article-title":"Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy","volume":"4","author":"Ferrara","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2019.08.011_bib34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.21037\/jtd.2018.12.47","article-title":"Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients\u2019 treatment","volume":"11","author":"Onesti","year":"2019","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.cpet.2019.08.011_bib35","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.cpet.2019.08.011_bib36","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Sa\u00e2da-Bouzid","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpet.2019.08.011_bib37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2016.06.017","article-title":"Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody","volume":"66","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.cpet.2019.08.011_bib38","first-page":"367","article-title":"Analysis of the abscopal effect with anti-PD1 therapy in patients with metastatic solid tumors","volume":"39","author":"Ribeiro Gomes","year":"2016","journal-title":"J\u00a0Immunother"},{"issue":"7","key":"10.1016\/j.cpet.2019.08.011_bib39","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group consensus response evaluation criteria in lymphoma","volume":"28","author":"Younes","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2019.08.011_bib40","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"10.1016\/j.cpet.2019.08.011_bib41","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2019.08.011_bib42","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.V128.22.1107.1107","article-title":"Pembrolizumab in relapsed\/refractory classical Hodgkin lymphoma: primary end point analysis of the phase II keynote-087 study","volume":"128","author":"Moskowitz","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cpet.2019.08.011_bib43","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/cas.13230","article-title":"Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma","volume":"108","author":"Maruyama","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cpet.2019.08.011_bib44","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00277-017-2931-z","article-title":"Low-dose pembrolizumab for relapsed\/refractory Hodgkin lymphoma: high efficacy with minimal toxicity","volume":"96","author":"Chan","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cpet.2019.08.011_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2967\/jnumed.117.193011","article-title":"18F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti-programmed death 1 immune checkpoint inhibitor","volume":"59","author":"Dercle","year":"2018","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2019.08.011_bib46","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ajh.25154","article-title":"Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a series from lYsa centers","volume":"93","author":"Rossi","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.cpet.2019.08.011_bib47","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/10428194.2018.1488254","article-title":"18F-FDG PET\/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors","volume":"6","author":"Castello","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cpet.2019.08.011_bib48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2017.12.015","article-title":"Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma","volume":"91","author":"Dercle","year":"2018","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.cpet.2019.08.011_bib49","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00259-018-4215-9","article-title":"Deauville score: the Phoenix rising from ashes","volume":"46","author":"Lopci","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2019.08.011_bib50","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jcyt.2018.10.003","article-title":"Early positron emission tomography\/computed tomography as a predictor of response after CTL019 chimeric antigen receptor-T-cell therapy in B-cell non-Hodgkin lymphomas","volume":"20","author":"Shah","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.cpet.2019.08.011_bib51","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","article-title":"Role of fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma","volume":"25","author":"Wang","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.cpet.2019.08.011_bib52","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J\u00a0Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2019.08.011_bib53","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1634\/theoncologist.2016-0419","article-title":"Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis","volume":"22","author":"Nishijima","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.cpet.2019.08.011_bib54","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-99-114101","article-title":"Analysis of immune-related adverse reactions in patients with classical Hodgkin lymphoma (cHL) on programmed death-1 (PD-1) inhibitors therapy","volume":"132","author":"Brave","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cpet.2019.08.011_bib55","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJMe1413488","article-title":"Release the hounds! Activating the T-cell response to cancer","volume":"372","author":"Sznol","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cpet.2019.08.011_bib56","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cpet.2019.08.011_bib57","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1097\/RLU.0000000000002453","article-title":"Predicting response to immunotherapy by evaluating tumors, lymphoid cell-rich organs, and immune-related adverse events using FDG-PET\/CT","volume":"44","author":"Nobashi","year":"2019","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cpet.2019.08.011_bib58","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cpet.2019.08.011_bib59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2019.08.011_bib60","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.4143\/crt.2017.473","article-title":"Delayed terminal ileal perforation in a relapsed\/refractory B-cell lymphoma patient with rapid remission following chimeric antigen receptor T-cell therapy","volume":"50","author":"Hu","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.cpet.2019.08.011_bib61","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells","volume":"155","author":"Wang","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.cpet.2019.08.011_bib62","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","article-title":"Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria","volume":"88","author":"Tazdait","year":"2018","journal-title":"Eur J Cancer"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859819300811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859819300811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:06:02Z","timestamp":1761563162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859819300811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1556859819300811"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2019.08.011","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Evidence on PET Response Assessment to Immunotherapy in Lymphomas","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2019.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}